Drug developers look at innovative mechanisms to tackle dry eye syndrome
Pharmaceutical Technology
SEPTEMBER 23, 2022
Dry eye syndrome (DES) is an indication whose mainstay treatment has been dominated by Allergan’s Restasis (cyclosporine ophthalmic emulsion 0.05%) ever since its launch in 2003 in the US. NOV-03 is also likely to be well-received by physicians and patients due to its favorable clinical and tolerability profile.
Let's personalize your content